Dihydroartemisinin

Phase 2Small molecule

Dihydroartemisinin is one of 9 small molecule programs targeting Locally Advanced Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Colorectal CancerActive, not recruiting

Acne VulgarisRecruiting

MAFLDRecruiting

Locally Advanced Colorectal CancerPhase 2

Active, not recruiting

Acne VulgarisPhase 1

Recruiting

MAFLDPreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Acne Vulgaris

#DrugCompanyPhaseTrials

Aklief

GGalderma R&D

Phase 3

2 2

Secretome

BBaermed

Phase 2

1 3

N-Acetyl-GED-0507-34-Levo

PPPM Services S.A.

Phase 3

3 4

Denifanstat

SSagimet Biosciences Inc.

Phase 3

1 5

Dihydroartemisinin

KKunming Pharmaceuticals, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Acne Vulgaris

NCT07007078

Phase 2Recruiting

Polycystic Ovary Syndrome

NCT06842524

Q2 2028

Phase 2Active, not recruiting

Locally Advanced Colorectal Cancer

NCT07801352

Clinical

Trials by Indication[1]

Plasmodium falciparum malaria1 trial

Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency

Completed·SSyamsudin Abdillah,Ph.D, Pharm D·Phase 2·NCT05829187·36 enrolled

Plasmodium Falciparum1 trial

Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua

Completed·SSyamsudin Abdillah,Ph.D, Pharm D·Phase 2·NCT06036030·50 enrolled

Acne Vulgaris1 trial

Efficacy of Dihydroartemisinin for Treating Acne Vulgaris

Recruiting·SShanghai Zhongshan Hospital·Phase 1·NCT07007078·60 enrolled

Polycystic Ovary Syndrome1 trial

Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome

Recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT06842524·150 enrolled

Systemic Lupus Erythematosus1 trial

Exploratory Study of DHA in Systemic Lupus Erythematosus Patients

Unknown status·KKunming Pharmaceuticals, Inc.·Phase 2·NCT03396393·120 enrolled

4 more indications

Efficacy1 trial

Efficacy of Dihydroartemisinin for Treating PCOS

Completed·SShanghai Zhongshan Hospital·Phase 2·NCT06417099·30 enrolled

PCOS1 trial

The Effect of Dihydroartemisinin in PCOS

Completed·SShanghai Zhongshan Hospital·Phase 4·NCT05465135·19 enrolled

Locally Advanced Colorectal Cancer1 trial

CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer

Active, not recruiting·SShanghai Changzheng Hospital·Phase 2·NCT07801352·15 enrolled

MAFLD1 trial

A Single-Arm, Proof-of-Concept Study of Dihydroartemisinin in Adults With Metabolic Associated Fatty Liver Disease

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Preclinical·NCT07679542·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Dihydroartemisinin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dihydroartemisinin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dihydroartemisinin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kunming Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKunming Pharmaceuticals, Inc.

Dihydroartemisinin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Trials by Indication[1]

Plasmodium falciparum malaria1 trial

Plasmodium Falciparum1 trial

Acne Vulgaris1 trial

Polycystic Ovary Syndrome1 trial

Systemic Lupus Erythematosus1 trial

Efficacy1 trial

PCOS1 trial

Locally Advanced Colorectal Cancer1 trial

MAFLD1 trial

References

Drug Info

Quick Facts

Related News